XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 20,551,957 13,881,186 18,286,917 13,835,989
Common Stock Options Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 14,693,276 13,204,775 13,978,339 13,360,000
Nonvested Restricted Stock Units        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 5,364,447 676,411 3,983,640 458,707
Nonvested Market-based Restricted Stock Units Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 494,234   324,938  
Common Stock Warrant Outstanding        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities       17,282